Stemline Therapeutics Inc (NASDAQ:STML) has been given an average rating of “Buy” by the nine analysts that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $26.00.

STML has been the subject of a number of analyst reports. Roth Capital set a $33.00 price objective on shares of Stemline Therapeutics and gave the stock a “buy” rating in a research report on Sunday, December 23rd. Piper Jaffray Companies upped their price objective on shares of Stemline Therapeutics to $30.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 26th. HC Wainwright reiterated a “buy” rating and issued a $38.00 price objective on shares of Stemline Therapeutics in a research report on Wednesday, December 26th. BidaskClub upgraded shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, December 27th. Finally, ValuEngine upgraded shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, December 28th.

In related news, CEO Ivan Bergstein sold 55,073 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $11.11, for a total transaction of $611,861.03. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Kenneth Hoberman sold 2,995 shares of the company’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $11.36, for a total transaction of $34,023.20. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 180,999 shares of company stock valued at $2,048,415. Insiders own 14.80% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Great West Life Assurance Co. Can acquired a new position in shares of Stemline Therapeutics during the 4th quarter worth about $47,000. Legal & General Group Plc raised its position in shares of Stemline Therapeutics by 27.1% during the 4th quarter. Legal & General Group Plc now owns 5,249 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 1,120 shares during the last quarter. Metropolitan Life Insurance Co. NY grew its stake in Stemline Therapeutics by 327.0% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 8,523 shares of the biopharmaceutical company’s stock valued at $81,000 after acquiring an additional 6,527 shares in the last quarter. Bank of America Corp DE grew its stake in Stemline Therapeutics by 56.8% during the 4th quarter. Bank of America Corp DE now owns 10,669 shares of the biopharmaceutical company’s stock valued at $101,000 after acquiring an additional 3,866 shares in the last quarter. Finally, Janney Montgomery Scott LLC purchased a new stake in Stemline Therapeutics during the 4th quarter valued at about $108,000. Hedge funds and other institutional investors own 47.32% of the company’s stock.

Shares of Stemline Therapeutics stock opened at $12.90 on Friday. The stock has a market capitalization of $562.05 million, a price-to-earnings ratio of -4.31 and a beta of 1.14. Stemline Therapeutics has a fifty-two week low of $7.82 and a fifty-two week high of $20.55.

Stemline Therapeutics (NASDAQ:STML) last issued its quarterly earnings data on Friday, March 15th. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.20). Sell-side analysts expect that Stemline Therapeutics will post -2.24 EPS for the current year.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Read More: Hedge Funds – How They Work For Investors

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.